English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Systemic drug delivery in schizophrenia is a major challenge, owing to the Blood-brain Barrier (BBB) and P-glycoprotein related effects. Consequently, herein an attempt is made to systemically deliver the most desirable schizophrenia drug, Quetiapine Fumarate (QF) via non-invasive intranasal route using Nanostructured Lipid Carrier (NLC) approach. Materials and Methods: The desired QF loaded NLCs were developed using central composite statistical design and the developed formulations were monitored for improving QF bioavailability and their brain targeting efficacies. Results: The optimized formulation displayed a 2-fold increase (compared to virgin QF) in ex-vivo nasal diffusion at the 6th hr, with no sign of structural damage (upon histopathological examinations). While, QF blood-brain ratio showed 10-fold increase for NLCs administered through nasal route (in comparison to intravenous route), thereby supporting prolonged retention of QF at the site of action. Similarly, the concentration of QF (in the brain) delivered via nasal route exhibited 4-fold increment at all-time points thereby supporting a potential nose to brain transport and effective bypassing of BBB. Conclusion: The results obtained infers that non-invasive intranasal route can be used as a potential alternative to conventional treatment options towards efficient management of schizophrenia.

indian journal of pharmaceutical education

Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterization and Pharmacokinetic Studies